Exchange: NASDAQ·Updated 04:04 PM EST

BHST News

News
all
press releases
BioHarvest Sciences Inc. (BHST) Reports Q3 Loss, Misses Revenue Estimates
BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of +6.25% and -18.31%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
BioHarvest Sciences Inc. (BHST) Reports Q3 Loss, Misses Revenue Estimates
BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of +6.25% and -18.31%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
MiNK Therapeutics, Inc. (INKT) delivered earnings and revenue surprises of +24.24% and +33.33%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
ImmunityBio (IBRX) delivered earnings and revenue surprises of -25.00% and -19.60%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Wave Life Sciences (WVE) delivered earnings and revenue surprises of +11.77% and +342.29%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of -30.77% and -10.51%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Celldex (CLDX) delivered earnings and revenue surprises of +9.62% and -98.75%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of +26.53% and +186.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of +100.00% and +1.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
BioHarvest Sciences Q1 Earnings Call Highlights...
Yahoo! Finance: News

Advertisement|Remove ads.